Five of these variants (in the JAK2, PRDM16, LRP1B, NIN, and NKX2-1 genes) were supported by repeated testing on an independent set of Singaporean NPC patients and unaffected Singaporean controls. This evidence concerns the gene NIN and nasopharyngeal carcinoma.